Barclays PLC Increases Stock Holdings in CG Oncology, Inc. (NASDAQ:CGON)

Barclays PLC raised its holdings in CG Oncology, Inc. (NASDAQ:CGONFree Report) by 331.1% in the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 90,520 shares of the company’s stock after buying an additional 69,523 shares during the quarter. Barclays PLC owned about 0.13% of CG Oncology worth $3,416,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in CGON. Amalgamated Bank boosted its stake in CG Oncology by 107.6% in the 3rd quarter. Amalgamated Bank now owns 1,621 shares of the company’s stock worth $61,000 after purchasing an additional 840 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of CG Oncology in the third quarter worth $241,000. Profund Advisors LLC acquired a new stake in shares of CG Oncology during the second quarter worth $300,000. HighVista Strategies LLC purchased a new stake in shares of CG Oncology during the third quarter valued at $594,000. Finally, SG Americas Securities LLC acquired a new position in shares of CG Oncology in the 3rd quarter valued at $664,000. Institutional investors and hedge funds own 26.56% of the company’s stock.

CG Oncology Stock Performance

Shares of CG Oncology stock opened at $28.13 on Tuesday. CG Oncology, Inc. has a twelve month low of $25.77 and a twelve month high of $50.23. The business has a 50-day moving average price of $34.40 and a 200 day moving average price of $34.66.

CG Oncology (NASDAQ:CGONGet Free Report) last announced its earnings results on Tuesday, November 12th. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.36) by $0.06. CG Oncology had a negative return on equity of 18.97% and a negative net margin of 10,642.98%. The business had revenue of $0.04 million during the quarter, compared to the consensus estimate of $0.30 million. As a group, equities analysts expect that CG Oncology, Inc. will post -1.32 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the company. UBS Group assumed coverage on CG Oncology in a research note on Thursday, October 24th. They set a “buy” rating and a $60.00 price target on the stock. Roth Mkm started coverage on shares of CG Oncology in a report on Tuesday, August 27th. They issued a “buy” rating and a $65.00 price objective on the stock. Roth Capital raised shares of CG Oncology to a “strong-buy” rating in a report on Tuesday, August 27th. HC Wainwright reaffirmed a “buy” rating and issued a $75.00 price target on shares of CG Oncology in a report on Friday, December 6th. Finally, Bank of America reiterated a “buy” rating and set a $65.00 price objective on shares of CG Oncology in a research note on Tuesday, October 8th. Eight research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $63.88.

Check Out Our Latest Report on CGON

Insider Buying and Selling at CG Oncology

In other CG Oncology news, Director Leonard E. Post sold 1,000 shares of the firm’s stock in a transaction on Friday, December 6th. The stock was sold at an average price of $34.54, for a total value of $34,540.00. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Hong Fang Song sold 700,000 shares of CG Oncology stock in a transaction on Monday, December 16th. The stock was sold at an average price of $28.00, for a total transaction of $19,600,000.00. Following the sale, the director now directly owns 3,003,931 shares in the company, valued at approximately $84,110,068. This trade represents a 18.90 % decrease in their position. The disclosure for this sale can be found here.

About CG Oncology

(Free Report)

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.

See Also

Want to see what other hedge funds are holding CGON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CG Oncology, Inc. (NASDAQ:CGONFree Report).

Institutional Ownership by Quarter for CG Oncology (NASDAQ:CGON)

Receive News & Ratings for CG Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CG Oncology and related companies with MarketBeat.com's FREE daily email newsletter.